Liver Fibrosis AssaysHelp improve the assessment of NAFLD/NASH and chronic liver disease patients at risk of disease progression

The ELF™ Test

Direct assessment of fibrosis has proven valuable for identifying patients at risk of progressing to cirrhosis and/or LREs.

Assess the risk of NAFLD/NASH progression and liver-related events with a simple blood test.

Assessing fibrosis risk with a more accessible blood test can help improve clinical and financial outcomes.

Helping to Reshape NASH Clinical Trials

Learn more about:

Videos

Hear from key opinion leaders about the rising prevalence of NAFLD/NASH and the need for non-invasive tests.

The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.

Keep up to date on the latest trends in healthcare. Read about current developments, new products and upcoming events.

Siemens Healthcare Limited ©2024Corporate InformationWebsite Privacy NoticeMarketing Privacy NoticeCookie PolicyTerms of Use3rd Party LicensesDigital Services ActModern Slavery Act